{"id":100,"date":"2016-01-26T01:10:09","date_gmt":"2016-01-26T01:10:09","guid":{"rendered":"http:\/\/dev.msapr.com\/main\/?page_id=100"},"modified":"2024-01-09T15:45:55","modified_gmt":"2024-01-09T15:45:55","slug":"interview-archives-before-2011","status":"publish","type":"page","link":"https:\/\/www.msapr.com\/main\/interview-archives-before-2011\/","title":{"rendered":"Interview Archives before 2011"},"content":{"rendered":"

Recent interviews<\/a><\/strong><\/p>\n

Archive Interviews through 2022<\/a><\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n
\n
\n

Issue 367: April 1, 2011<\/h4>\n

\"367\"Scott Minick,<\/strong> President and CEO, BIND Biosciences, on the company’s therapeutic targeted nanoparticle technology.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 366: March 25, 2011<\/h4>\n

\"366\"Robert Shore, M.D., CEO,<\/strong> and Timothy Sullivan,<\/strong> Executive Vice President,
\nCornerstone Pharmaceuticals, on the company\u2019s drug delivery technology targeting cancer cell metabolism.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 364: March 11, 2011<\/h4>\n

\"364\"Robert L. Kirkman, M.D., <\/strong>President and CEO, and Scott Peterson, Ph.D.,<\/strong> Vice President of Research and Development, Oncothyreon, on the company\u2019s PI3K inhibitor.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 363: March 4, 2011<\/h4>\n

\"363\"Ernest Wong, Ph.D., M.B.A.,<\/strong> Vice President, YM Biosciences, about the company’s JAK inhibitor program in myelofibrosis.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 362: February 25, 2011<\/h4>\n

\"362\"Masayuki Yazawa, Ph.D.,<\/strong> Postdoctoral Research Fellow, Stanford University, on the use of iPS cells to treat Timothy Syndrome.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 361: February 18, 2011<\/h4>\n

\"361\"William S. Marshall, Ph.D.<\/strong> President and CEO of miRagen Therapeutics, about the company’s miRNA-targeted drugs.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 358: January 28, 2011<\/h4>\n

\"361\"Arthur Sands, M.D., Ph.D.,<\/strong> President and CEO, Lexicon Pharmaceuticals, about the company’s development programs and partnering strategy.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 356: January 14, 2011<\/h4>\n

\"356\"Katrine Bosley,<\/strong> CEO of Avila Therapeutics, about the company’s discovery platform for targeted covalent drugs.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 354: December 23, 2010<\/h4>\n

\"354\"Robert Kneller, J.D., M.D., M.P.H.,<\/strong> Professor, Research Center for Advanced Science and Technology (RCAST), University of Tokyo, on the differences between pharma and academia in drug discovery innovation.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 353: December 17, 2010<\/h4>\n

\"353\"Aris Persidis, PhD.,<\/strong> President and Co-Founder, Biovista Inc., on using mechanism of action to predict safety and efficacy.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 351: December 3, 2010<\/h4>\n

\"346\"Thomas Hughes, Ph.D.<\/strong>,<\/strong> President and CEO of Zafgen Inc., on the company’s lead candidate compound that promotes sustained weight loss through MetAP2 inhibition<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 350: November 19, 2010<\/h4>\n

\"350-1\"\"350-2\"\"350-3\"Eggehard Holler, Ph.D.<\/strong>, University of Regensburg, Julia Ljubimova, M.D., Ph.D.<\/strong>, Cedars-Sinai Medical Center, and Maurizio Vecchione<\/strong>, CEO, Arrogene Nanotechnology, on a nanoconjugate technology for treating brain …<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 348: November 5, 2010<\/h4>\n

\"348\"John E. Wennberg, M.D., M.P.H.,<\/strong> Peggy Y. Thomson Professor in the Evaluative Clinical Sciences, Dartmouth Medical School, on a rational approach to supply and demand in medicine.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 346: October 22, 2010<\/h4>\n

\"346\"Tillman U. Gerngross, Ph.D.<\/strong>,<\/strong> CEO of Adimab Inc., on the company\u2019s novel antibody discovery platform.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 343: October 1, 2010<\/h4>\n

\"343\"Kobi M. Sethna, <\/strong> President and CEO, Nereus Pharmaceuticals, on leveraging marine microbes as a source of novel pharmaceutical agents.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 342: September 24, 2010<\/h4>\n

\"342\"Richard L. Atkinson, M.D., <\/strong>Clinical Professor of Pathology, Virginia Commonwealth University, and President, Obetech, LLC, on the evidence for a causal link between AD36 and obesity.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 341: September 17, 2010<\/h4>\n

\"341\"Kathleen Sereda Glaub, <\/strong>President, Plexxikon, on the company’s lead drug candidate for melanoma.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 337: August 20, 2010<\/h4>\n

\"337\"Harald Fricke, M.D., Ph.D.,<\/strong> CMO and COO, Apogenix, on an innovative therapeutic approach to treating glioblastoma.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 336: August 6, 2010<\/h4>\n

\"336\"Stephen Engle,<\/strong> Chairman and CEO, XOMA, on developing a therapeutic antibody-based approach to diabetes treatment.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 334: July 23, 2010<\/h4>\n

\"334\"Soichi Matsuno,<\/strong> Advisor, Eisai Co., Ltd., on how the company\u2019s pioneering spirit has contributed to its global expansion.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 333: July 15, 2010<\/h4>\n

\"333\"Maria L. Maccecchini, Ph.D.,<\/strong> President & CEO, QR Pharma, on an approach to inhibiting amyloid formation in targeting mild cognitive impairment and Alzheimer\u2019s disease.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 332: July 7, 2010<\/h4>\n

\"332\"Marc Cantillon, M.D.,<\/strong> Director of the Coalition Against Major Diseases at the Critical Path Institute, on accelerating Alzheimer\u2019s drug development through data collaboration.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 328: June 4, 2010<\/h4>\n

\"328\"Gordon McCauley,<\/strong> President and CEO, Allon Therapeutics Inc., on targeting neurodegenerative diseases with activity-dependent neuroprotective protein.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 326: May 21, 2010<\/h4>\n

\"326\"\"326\"Robert Gould, Ph.D.,<\/strong> President and CEO, and Jason Rhodes,<\/strong> EVP and Chief Business Officer of Epizyme, on transforming cancer therapy via HMT inhibition.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 325: May 14, 2010<\/h4>\n

\"325\"Tom Smart,<\/strong> Chairman and CEO, AnaptysBio, on leveraging a novel platform for antibody generation.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 322: April 23, 2010<\/h4>\n

\"322\"Roger H. Unger, M.D.,<\/strong> Professor of Internal Medicine, University of Texas South Western Medical Center, on the comparison of leptin and insulin levels in mouse models of type 1 diabetes.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 321: April 16, 2010<\/h4>\n

\"321\"Adam Bosworth,<\/strong> Founder and CTO of Keas, on using intelligent computing to improve patient outcomes.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 316: March 12, 2010<\/h4>\n

\"316\"Christopher S. Meldrum,<\/strong> President, Pique Therapeutics, on non-immunogenic cancer treatment using allogenic vaccine therapies.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 314: February 26, 2010<\/h4>\n

\"314\"Andrew M. Thompson<\/strong>, Co-Founder and CEO, Proteus Biomedical, on the company’s advancements in intelligent medicine.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 312: February 12, 2010<\/h4>\n

\"312\"Stephen H. Friend, M.D., Ph.D.,<\/strong> President, CEO and Co-Founder, Sage Bionetworks, on the development of a shared data repository of clinical data to improve disease modeling.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 309: January 22, 2010<\/h4>\n

\"309\"Alpheus Bingham, Ph.D.,<\/strong> Founder and Director, InnoCentive Inc., on an incentive-based open innovation model for helping organizations solve research problems.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 305: December 18, 2009<\/h4>\n

\"305\"\"305\"Per Olof Wallstr\u00f6<\/strong>m, <\/strong>President and CEO, and Erika S\u00f6<\/strong>derberg Johnson, <\/strong>CFO, Karo Bio, on the development of innovative therapeutics targeting nuclear receptors.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 304: December 11, 2009<\/h4>\n

\"304\"Joshua Kazam,<\/strong> President and CEO, Nile Therapeutics, on the company’s application of natriuretic peptides to treat heart failure.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 303: December 4, 2009<\/h4>\n

\"303\"Kees Been,<\/strong> President and CEO, EnVivo Pharmaceuticals, on enhancing cognitive function in Alzheimer’s disease and schizophrenia patients.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 302: November 20, 2009<\/h4>\n

\"302\"Benjamin Heywood, <\/strong>Co-Founder and President, PatientsLikeMe, on the company’s platform for connecting patients and pharma through social networking.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 301: November 13, 2009<\/h4>\n

\"301\"Randall L. Carpenter, M.D.,<\/strong> Co-Founder, President and CEO, Seaside Therapeutics, on the development of novel therapies for Fragile X Syndrome.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 300: November 6, 2009<\/h4>\n

\"300\"Joseph P. Pieroni,<\/strong> CEO, Daiichi Sankyo Inc., on the company’s marketing strategy for Effient.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 299: October 30, 2009<\/h4>\n

\"299\"Judy Mikovits,<\/strong> Ph.D<\/strong>, Director of Research at the Whittemore Peterson Institute, on the correlation between XMRV and Chronic Fatigue Syndrome.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 296: October 9, 2009<\/h4>\n

\"296\"David Rose,<\/strong> CEO, Vitality, on GlowCaps, the company’s breakthrough technology to promote medicine adherence.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 295: October 2, 2009<\/h4>\n

\"295\"Jennifer A. Low, MD, PhD, <\/strong>Global Clinical Lead for GTC-0449, Genentech, on Promising Early Clinical Results for a Hedgehog Inhibitor in Cancer.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 293: September 18, 2009<\/h4>\n

\"293\"Julia P. Gregory, <\/strong>President and CEO, Five Prime Therapeutics, Inc., on the company’s unique discovery platform.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 290: August 28, 2009<\/h4>\n

\"290\"Shingo Kajimura, Ph. D.<\/strong>,<\/strong> Instructor in Cell Biology, Dana-Farber Cancer Institute, on the transcription mechanism of brown fat formation from myoblastic precursors.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 289: August 21, 2009<\/h4>\n

\"289\"<\/strong>Robert H. Uhl, <\/strong> Senior Director of Investor Relations, Halozyme Therapeutics, on the company’s recombinant human hyaluronidase-based drug delivery platform.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 288: August 14, 2009<\/h4>\n

\"288\"<\/strong>Dr. Gail Naughton,<\/strong> CEO, Histogen, Inc., on the use of embryonic protein WNT7A to counteract hair loss.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 286: July 31, 2009<\/h4>\n

\"286\"<\/strong>Neil Warma<\/strong>, President and CEO of Opexa Therapeutics, on an individually tailored cell therapy for multiple sclerosis.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 283: July 10, 2009:<\/h4>\n

\"283\"<\/strong>Vijay B. Samant, <\/strong>President and CEO, Vical, Inc., on the potential applications of its DNA-based vaccine delivery technology.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 282: June 26, 2009<\/h4>\n

\"282\"<\/strong>Robert Gatenby, M.D., <\/strong>Chairman of the Departments of Diagnostic Imaging and Integrative Mathematical Oncology, H. Lee Moffitt Cancer Center, on the adaptive therapy approach to cancer treatment.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 281: June 19, 2009<\/h4>\n

\"281\"<\/strong>Vince Kuraitis, <\/strong>Principal and Founder, Better Health Technologies, LLC, on the future of the disease management industry.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 280: June 12, 2009<\/h4>\n

\"280\"<\/strong>Gregory Perry, <\/strong>Senior Vice President and CFO, ImmunoGen, Inc., on the role of ImmunoGen’s Targeted Antibody Payload (TAP) technology in developing better tolerated anticancer drugs.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 278: May 29, 2009<\/h4>\n

\"278\"<\/strong>Saeid Akhtari, <\/strong>Co-Founder, President and CEO, NextBio, on the company’s bioinformation search platform.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 277: May 22, 2009<\/h4>\n

\"277\"<\/strong>Shawn Lyndon, <\/strong>Founder, President and CEO, Orasi Medical, on the use of magnetoencephalography (MEG) to diagnose neurological diseases.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 276: May 15, 2009<\/h4>\n

\"276\"<\/strong>Eric Elliott, <\/strong>President, CIGNA Pharmacy Management, on CIGNA’s recent performance-based contract with Merck.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 275: May 8, 2009<\/h4>\n

\"275\"<\/strong>Edward Abrahams, Ph.D., <\/strong>Executive Director, Personalized Medicine Coalition, on the status of personalized medicine in the United States.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 270: April 3, 2009<\/h4>\n

\"270\"<\/strong>Bruce S. Auerbach, M.D., FACEP, <\/strong>President, Massachusetts Medical Society, on the implications of Massachusetts’ shortage of primary care physicians.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 269: March 27, 2009:<\/h4>\n

\"269\"<\/strong>Yoshimi Kuroiwa, Ph.D., <\/strong>Executive Research Director, Hematech, Inc. on the production of polyclonal antibodies using genetically modified cattle.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 264: February 20, 2009<\/h4>\n

\"264\"<\/strong>Vincent Mutel, Ph.D., <\/strong>Co-Founder, Vice Chairman and CEO, Addex Pharmaceuticals, on the advantages of allosteric modulators for G-protein coupled receptors (GPCRs).<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 263: February 13, 2009<\/h4>\n

\"263\"<\/strong>Jason Hwang, M.D., <\/strong>Executive Director of Healthcare, Innosight Institute, on the forces shaping change in the pharmaceutical industry as articulated in his book, The Innovator’s Prescription.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 260: January 13, 2009<\/h4>\n

\"260\"<\/strong>Scott Weir, PharmD, Ph.D., <\/strong>Professor and Director of the Office of Therapeutics, Discovery and Development for the University of Kansas Medical Center, on his group’s drug development partnership with the Leukemia & Lymphoma Society (LLS).<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 259: January 16, 2009<\/h4>\n

\"259\"<\/strong>Mollie Shields-Uehling, <\/strong> President & CEO, SAFE-BioPharma Association, on creating a digital signature standard for the pharmaceutical industry.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 255: December 5, 2008<\/h4>\n

\"255\"<\/strong>Les Jordan, <\/strong> Life Sciences Industry Technology Strategist, Microsoft Corporation, on bringing order to the cacophony of data.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 254: Nobember 21, 2008<\/h4>\n

\"254\"<\/strong>Thomas Neyarapally, <\/strong> Vice President, Corporate Strategy and Intellectual Property, Gene Network Sciences, on interrogating data to identify novel drug targets and drug effects.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 252: Nobember 7, 2008<\/h4>\n

\"252\"<\/strong>Robert S. Becker, Ph.D., MBA, <\/strong> Vice President, Business Development, VaxInnate Corporation, on developing a potent universal flu vaccine.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 251: October 31, 2008<\/h4>\n

\"251\"<\/strong>James J. O’Mara, <\/strong> Vice President, Business Development, Ironwood Pharmaceuticals, Inc., on moving into phase 3 with a novel treatment for gastrointestinal disorders..<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 248: October 10, 2008<\/h4>\n

\"248\"<\/strong>Hironori Hozoji, <\/strong> Investment Officer, JAFCO Life Science Investment, on cultivating portfolio companies with better exit possibilities.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 246: September 26, 2008<\/h4>\n

\"246\"<\/strong>David Steinberg<\/strong>, CEO, Enlight Biosciences, and Senior Principal, Puretech Ventures, on developing technologies for pharma R&D.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 245: September 19, 2008<\/h4>\n

\"245\"<\/strong>Danong Chen, Ph.D.<\/strong>, President and CEO, Theranostics Health, on protein profiling and targeted therapies.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 244: September 12, 2008<\/h4>\n

\"244\"<\/strong>Javier Gonzalez-Maeso, Ph.D.<\/strong>, Assistant Professor, Departments of Neurology and Psychiatry, Mount Sinai School of Medicine, on new perspectives on the molecular mechanisms of schizophrenia.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 241: August 22, 2008:<\/h4>\n

\"241\"<\/strong>Ellen Coleman<\/strong>, Executive Vice President, Emerging Med, on matching patients with clinical trials for cancer treatments.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 240: August 8, 2008<\/h4>\n

\"240\"<\/strong>Nicholas J. Seay<\/strong>, Chief Technology Officer, Cellular Dynamics International, on the next stage in cell-based drug toxicity screening.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 239: August 1, 2008<\/h4>\n

\"239\"<\/strong>Jacqueline A. French, MD<\/strong>, Professor of Neurology, New York University School of Medicine, on treatment choice and development challenges for anti-epileptic drugs.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 233: June 13, 2008<\/h4>\n

\"233\"<\/strong>Howard Martin Fillit, M.D.<\/strong>, Executive Director, Alzheimer’s Drug Discovery Foundation, on the role of venture philanthropy in accelerating drug discovery for Alzheimer’s disease.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 231: May 30, 2008<\/h4>\n

\"231\"<\/strong>Jayakrishna Ambati, M.D.<\/strong>, Professor of Physiology and Professor & Vice-Chair of Ophthalmology and Visual Sciences, University of Kentucky, on the mechanism of siRNA treatments in clinical development for macular degeneration.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 227: May 2, 2008<\/h4>\n

\"227\"<\/strong>Keizo Koya, Ph.D.<\/strong>, Senior Vice President, Drug Development, Synta Pharmaceuticals Corp., on killing cancer cells through oxidative stress.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 225: April 18, 2008<\/h4>\n

\"225\"<\/strong>Anthony J. Varano, Jr.<\/strong>, Founder, President and CEO, DSG Inc., on opening doors to clinical trial efficiencies and savings with EDC software.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 224: April 11, 2008:<\/h4>\n

\"224\"<\/strong>David G. Stevenson, S.M., Ph.D.<\/strong>, Assistant Professor, Department of Health Care Policy, Harvard Medical School, on the special challenges posed by Part D for nursing home residents.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 223: April 4, 2008<\/h4>\n

\"223\"<\/strong>Joe Dougherty, Ph.D.<\/strong>, Co-Founder and Partner, Seaview Securities LLC, on LigoCyte and prospects in the financing market for biotech ventures.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 221: March 20, 2008<\/h4>\n

\"221\"<\/strong>Adam J. Fein, Ph.D.<\/strong>, Founder and President, Pembroke Consulting, Inc., on the interface between PBMs and retail pharmacies.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 217: February 22, 2008<\/h4>\n

\"217\"<\/strong>Bernhardt L. Trout<\/strong>, Professor, Department of Chemical Engineering, Massachusetts Institute of Technology, on optimizing drug manufacturing through continuous processing.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 215: February 8, 2008<\/h4>\n

\"215\"<\/strong>Akiko Yabuuchi, Ph.D.<\/strong>, Research Associate, Harvard Medical School, Children’s Hospital Boston, on a comparison of stem-cell research in Japan and the United States.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 213: January 25, 2008<\/h4>\n

\"213\"<\/strong>Joshua J. Spooner, PharmD, MS<\/strong>, Director of Clinical and Outcomes Services, Advanced Concepts Institute, University of the Sciences in Philadelphia, on the importance of producing high-quality dossiers for health plans.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n
\n
\n

Issue 293: September 18, 2009<\/h4>\n

\"293\"Julia P. Gregory, <\/strong>President and CEO, Five Prime Therapeutics, Inc., on the company’s unique discovery platform.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 290: August 28, 2009<\/h4>\n

\"290\"Shingo Kajimura, Ph. D.<\/strong>,<\/strong> Instructor in Cell Biology, Dana-Farber Cancer Institute, on the transcription mechanism of brown fat formation from myoblastic precursors.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 289: August 21, 2009<\/h4>\n

\"289\"<\/strong>Robert H. Uhl, <\/strong> Senior Director of Investor Relations, Halozyme Therapeutics, on the company’s recombinant human hyaluronidase-based drug delivery platform.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 288: August 14, 2009<\/h4>\n

\"288\"<\/strong>Dr. Gail Naughton,<\/strong> CEO, Histogen, Inc., on the use of embryonic protein WNT7A to counteract hair loss.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 286: July 31, 2009<\/h4>\n

\"286\"<\/strong>Neil Warma<\/strong>, President and CEO of Opexa Therapeutics, on an individually tailored cell therapy for multiple sclerosis.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 283: July 10, 2009:<\/h4>\n

\"283\"<\/strong>Vijay B. Samant, <\/strong>President and CEO, Vical, Inc., on the potential applications of its DNA-based vaccine delivery technology.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 282: June 26, 2009<\/h4>\n

\"282\"<\/strong>Robert Gatenby, M.D., <\/strong>Chairman of the Departments of Diagnostic Imaging and Integrative Mathematical Oncology, H. Lee Moffitt Cancer Center, on the adaptive therapy approach to cancer treatment.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 281: June 19, 2009<\/h4>\n

\"281\"<\/strong>Vince Kuraitis, <\/strong>Principal and Founder, Better Health Technologies, LLC, on the future of the disease management industry.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 280: June 12, 2009<\/h4>\n

\"280\"<\/strong>Gregory Perry, <\/strong>Senior Vice President and CFO, ImmunoGen, Inc., on the role of ImmunoGen’s Targeted Antibody Payload (TAP) technology in developing better tolerated anticancer drugs.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 278: May 29, 2009<\/h4>\n

\"278\"<\/strong>Saeid Akhtari, <\/strong>Co-Founder, President and CEO, NextBio, on the company’s bioinformation search platform.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 277: May 22, 2009<\/h4>\n

\"277\"<\/strong>Shawn Lyndon, <\/strong>Founder, President and CEO, Orasi Medical, on the use of magnetoencephalography (MEG) to diagnose neurological diseases.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 276: May 15, 2009<\/h4>\n

\"276\"<\/strong>Eric Elliott, <\/strong>President, CIGNA Pharmacy Management, on CIGNA’s recent performance-based contract with Merck.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 275: May 8, 2009<\/h4>\n

\"275\"<\/strong>Edward Abrahams, Ph.D., <\/strong>Executive Director, Personalized Medicine Coalition, on the status of personalized medicine in the United States.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 270: April 3, 2009<\/h4>\n

\"270\"<\/strong>Bruce S. Auerbach, M.D., FACEP, <\/strong>President, Massachusetts Medical Society, on the implications of Massachusetts’ shortage of primary care physicians.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 269: March 27, 2009:<\/h4>\n

\"269\"<\/strong>Yoshimi Kuroiwa, Ph.D., <\/strong>Executive Research Director, Hematech, Inc. on the production of polyclonal antibodies using genetically modified cattle.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 264: February 20, 2009<\/h4>\n

\"264\"<\/strong>Vincent Mutel, Ph.D., <\/strong>Co-Founder, Vice Chairman and CEO, Addex Pharmaceuticals, on the advantages of allosteric modulators for G-protein coupled receptors (GPCRs).<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 263: February 13, 2009<\/h4>\n

\"263\"<\/strong>Jason Hwang, M.D., <\/strong>Executive Director of Healthcare, Innosight Institute, on the forces shaping change in the pharmaceutical industry as articulated in his book, The Innovator’s Prescription.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 260: January 13, 2009<\/h4>\n

\"260\"<\/strong>Scott Weir, PharmD, Ph.D., <\/strong>Professor and Director of the Office of Therapeutics, Discovery and Development for the University of Kansas Medical Center, on his group’s drug development partnership with the Leukemia & Lymphoma Society (LLS).<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 259: January 16, 2009<\/h4>\n

\"259\"<\/strong>Mollie Shields-Uehling, <\/strong> President & CEO, SAFE-BioPharma Association, on creating a digital signature standard for the pharmaceutical industry.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 255: December 5, 2008<\/h4>\n

\"255\"<\/strong>Les Jordan, <\/strong> Life Sciences Industry Technology Strategist, Microsoft Corporation, on bringing order to the cacophony of data.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 254: Nobember 21, 2008<\/h4>\n

\"254\"<\/strong>Thomas Neyarapally, <\/strong> Vice President, Corporate Strategy and Intellectual Property, Gene Network Sciences, on interrogating data to identify novel drug targets and drug effects.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 252: Nobember 7, 2008<\/h4>\n

\"252\"<\/strong>Robert S. Becker, Ph.D., MBA, <\/strong> Vice President, Business Development, VaxInnate Corporation, on developing a potent universal flu vaccine.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 251: October 31, 2008<\/h4>\n

\"251\"<\/strong>James J. O’Mara, <\/strong> Vice President, Business Development, Ironwood Pharmaceuticals, Inc., on moving into phase 3 with a novel treatment for gastrointestinal disorders..<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 248: October 10, 2008<\/h4>\n

\"248\"<\/strong>Hironori Hozoji, <\/strong> Investment Officer, JAFCO Life Science Investment, on cultivating portfolio companies with better exit possibilities.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 246: September 26, 2008<\/h4>\n

\"246\"<\/strong>David Steinberg<\/strong>, CEO, Enlight Biosciences, and Senior Principal, Puretech Ventures, on developing technologies for pharma R&D.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 245: September 19, 2008<\/h4>\n

\"245\"<\/strong>Danong Chen, Ph.D.<\/strong>, President and CEO, Theranostics Health, on protein profiling and targeted therapies.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 244: September 12, 2008<\/h4>\n

\"244\"<\/strong>Javier Gonzalez-Maeso, Ph.D.<\/strong>, Assistant Professor, Departments of Neurology and Psychiatry, Mount Sinai School of Medicine, on new perspectives on the molecular mechanisms of schizophrenia.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 241: August 22, 2008:<\/h4>\n

\"241\"<\/strong>Ellen Coleman<\/strong>, Executive Vice President, Emerging Med, on matching patients with clinical trials for cancer treatments.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 240: August 8, 2008<\/h4>\n

\"240\"<\/strong>Nicholas J. Seay<\/strong>, Chief Technology Officer, Cellular Dynamics International, on the next stage in cell-based drug toxicity screening.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 239: August 1, 2008<\/h4>\n

\"239\"<\/strong>Jacqueline A. French, MD<\/strong>, Professor of Neurology, New York University School of Medicine, on treatment choice and development challenges for anti-epileptic drugs.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 233: June 13, 2008<\/h4>\n

\"233\"<\/strong>Howard Martin Fillit, M.D.<\/strong>, Executive Director, Alzheimer’s Drug Discovery Foundation, on the role of venture philanthropy in accelerating drug discovery for Alzheimer’s disease.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 231: May 30, 2008<\/h4>\n

\"231\"<\/strong>Jayakrishna Ambati, M.D.<\/strong>, Professor of Physiology and Professor & Vice-Chair of Ophthalmology and Visual Sciences, University of Kentucky, on the mechanism of siRNA treatments in clinical development for macular degeneration.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 227: May 2, 2008<\/h4>\n

\"227\"<\/strong>Keizo Koya, Ph.D.<\/strong>, Senior Vice President, Drug Development, Synta Pharmaceuticals Corp., on killing cancer cells through oxidative stress.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 225: April 18, 2008<\/h4>\n

\"225\"<\/strong>Anthony J. Varano, Jr.<\/strong>, Founder, President and CEO, DSG Inc., on opening doors to clinical trial efficiencies and savings with EDC software.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 224: April 11, 2008:<\/h4>\n

\"224\"<\/strong>David G. Stevenson, S.M., Ph.D.<\/strong>, Assistant Professor, Department of Health Care Policy, Harvard Medical School, on the special challenges posed by Part D for nursing home residents.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 223: April 4, 2008<\/h4>\n

\"223\"<\/strong>Joe Dougherty, Ph.D.<\/strong>, Co-Founder and Partner, Seaview Securities LLC, on LigoCyte and prospects in the financing market for biotech ventures.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 221: March 20, 2008<\/h4>\n

\"221\"<\/strong>Adam J. Fein, Ph.D.<\/strong>, Founder and President, Pembroke Consulting, Inc., on the interface between PBMs and retail pharmacies.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 217: February 22, 2008<\/h4>\n

\"217\"<\/strong>Bernhardt L. Trout<\/strong>, Professor, Department of Chemical Engineering, Massachusetts Institute of Technology, on optimizing drug manufacturing through continuous processing.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 215: February 8, 2008<\/h4>\n

\"215\"<\/strong>Akiko Yabuuchi, Ph.D.<\/strong>, Research Associate, Harvard Medical School, Children’s Hospital Boston, on a comparison of stem-cell research in Japan and the United States.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 213: January 25, 2008<\/h4>\n

\"213\"<\/strong>Joshua J. Spooner, PharmD, MS<\/strong>, Director of Clinical and Outcomes Services, Advanced Concepts Institute, University of the Sciences in Philadelphia, on the importance of producing high-quality dossiers for health plans.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n
\n
\n

Issue 208: December 14, 2007<\/h4>\n

\"208\"<\/strong>Boro Dropulic, Ph.D., M.B.A<\/strong>, Founder and Chief Executive Officer, Lentigen, on the uses and advantages of his company’s Lentiviral Vector Platform.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 205: November 16, 2007<\/h4>\n

\"205\"<\/strong>Gerald Bernstein, M.D., F.A.C.P.<\/strong>, Vice President for Medical Affairs, Generex Biotechnology, on Generex’s Oral-lyn insulin product and the advantages of buccal delivery.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 204: November 9, 2007<\/h4>\n

\"204\"<\/strong>Elizabeth Haanes, Ph.D.<\/strong>, Director, Sterne, Kessler, Goldstein & Fox P.L.L.C., on newly proposed Patent Office rules that would pose a hardship for the pharmaceutical industry.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 203: November 2, 2007<\/h4>\n

\"203\"<\/strong>Michael J. Krische, Ph.D.<\/strong>, Professor, Department of Chemistry and Biochemistry, University of Texas at Austin, on a byproduct-free method of creating carbon-carbon bonds through hydrogenation.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 200: October 12, 2007<\/h4>\n

\"200\"<\/strong>William C. Crawford<\/strong> , Director of Industry Relations, Children’s Hospital Informatics Program, on creating a market for personally-controlled health records.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 199: October 5, 2007<\/h4>\n

\"148\"<\/strong>Gokhan S. Hotamisligil, M.D., Ph.D.<\/strong> , Chair, Department of Genetics and Complex Diseases, and J.S. Simmons Professor of Genetics & Metabolism, Harvard School of Public Health, on therapies at the interface of metabolic and inflammatory diseases.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 198: September 28, 2007<\/h4>\n

\"198\"<\/strong>Daniel J. Carlat, M.D.<\/strong> , Assistant Clinical Professor of Psychiatry, Tufts University School of Medicine, and Editor-in-Chief, The Carlat Psychiatry Report, on industry sponsorship of continuing medical education.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 197: September 21, 2007<\/h4>\n

\"197\"<\/strong>Paul Burn, Ph.D.<\/strong> , Senior Vice President of Research & Development, Juvenile Diabetes Research Foundation (JDRF), on JDRF’s increased focus on translational and clinical research.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 196: September 14, 2007<\/h4>\n

\"196\"<\/strong>Sara Rosenbaum,<\/strong> Chair, Department of Health Policy, School of Public Health and Health Services, George Washington University Medical Center, on the SCHIP reauthorization bill.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 194: August 31, 2007<\/h4>\n

\"194\"<\/strong>Frank Burroughs<\/strong> , President, Abigail Alliance for Better Access to Developmental Drugs, on his organization’s push for ACCESS legislation.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 192: August 10, 2007<\/h4>\n

\"\"<\/strong>Pieter Muntendam M.D.<\/strong> , President and CEO, and Robert N. McBurney, Ph.D.<\/strong>, Senior Vice President, Research & Development, and Chief Scientific Officer, BG Medicine, on creating biomarkers as decision tools for molecular medicine.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 189: July 20, 2007<\/h4>\n

\"189\"<\/strong>J. Scott Tarrant<\/strong> , VP of Business Development, Xceleron Inc., on prioritizing compounds with human PK data through microdosing studies.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 188: July 13, 2007<\/h4>\n

\"188\"<\/strong>Barry J. Schindler, <\/strong> Shareholder, Greenberg Traurig, LLP, on unresolved points of contention in the proposed patent reform bill.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 187: July 6, 2007<\/h4>\n

\"187\"<\/strong>Eileen Hilton, M.D.<\/strong> , President and CEO, Biomedical Research Alliance of New York (BRANY), on BRANY’s one-stop service for multi-center clinical trials.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 186: June 29, 2007<\/h4>\n

\"186\"<\/strong>Naomi Aronson, Ph.D.<\/strong> , Executive Director, Blue Cross and Blue Shield Association (BCBSA) Technology Evaluation Center (TEC), on technology assessments and comparative effectiveness reviews.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 182: June 29, 2007<\/h4>\n

\"182\"<\/strong>Michael Milburn, Ph.D.<\/strong> , Chief Scientific Officer, Metabolon, Inc., on using metabolomics in biomarker discovery and compound profiling.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 179: May 11, 2007<\/h4>\n

\"179\"<\/strong>Stuart W. Peltz, Ph.D.<\/strong> , President and CEO, PTC Therapeutics, on his company’s approach of using small molecules to regulate protein synthesis.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 178: May 4, 2007<\/h4>\n

\"178\"<\/strong>Bruce W. MacLennan,<\/strong> Partner, Herrick Feinstein LLP, on negotiating licensing deals with biotech companies.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 176: April 20, 2007<\/h4>\n

\"176\"<\/strong>Daniel B. Ravicher<\/strong> , President and Executive Director, Public Patent Foundation, on challenging bad patents to serve the public interest.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 175: April 13, 2007<\/h4>\n

\"175\"<\/strong>Jacques E. Rossouw, M.D.<\/strong> , Chief of Women’s Health Initiative Branch, National Heart, Lung, and Blood Institute, NIH, on refining treatment recommendations for hormone therapy.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 174: March 30, 2007<\/h4>\n

\"174\"<\/strong>Wayne Koberstein<\/strong> , Consultant, on trends and developments among some of the key companies within the pharmaceutical industry.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 172: March 16, 2007<\/h4>\n

\"172\"<\/strong>William A. Sarraille<\/strong> , Partner, Sidley Austin LLP, on the potential impact of CMS’s proposed rules regarding Average Manufacturer Price (AMP) in Medicaid<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 171: March 9, 2007<\/h4>\n

\"171\"<\/strong>Mark Kessel<\/strong> , Co-Founder and Managing Director, Symphony Capital, on Symphony Capital’s partnership approach to financing the development of early clinical-stage compounds.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 169: February 23, 2007<\/h4>\n

\"169\"<\/strong>William L. Warren<\/strong> , Partner, Sutherland Asbill & Brennan LLP, on Representative Waxman’s proposed bill on follow-on biologics.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 167: February 9, 2007<\/h4>\n

\"167\"<\/strong>Lynn E. Eccleston<\/strong> , Attorney, McGuire Woods LLP, on the ramifications of the Supreme Court’s decision on declaratory judgments in MedImmune v. Genentech.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 164 and 165: January 19 and 26, 2007<\/h4>\n

\"164\"<\/strong>Shin-Ichiro Imai, M.D., Ph.D.<\/strong> Assistant Professor, Molecular Biology and Pharmacology, Washington University School of Medicine, on research into Sir2 and longevity.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 161: December 22, 2006<\/h4>\n

\"161\"<\/strong>Kenneth A. Getz, <\/strong> Senior Research Fellow, Tufts Center for the Study of Drug Development, on factors affecting speed and efficiency in clinical development.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 160: December 15, 2006<\/h4>\n

\"160\"<\/strong>Louis A. Tartaglia, Ph.D., <\/strong> Senior Vice President and General Manager of Drug Repositioning and Selection, Gene Logic, on Gene Logic’s drug repositioning business.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 159: December 8, 2006<\/h4>\n

\"159\"<\/strong>Gary P. Pisano<\/strong>, Professor, Harvard Business School, on his new book on the biotechnology industry, Science Business<\/em>.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 156: November 10, 2006<\/h4>\n

\"156\"<\/strong>Richard P. Burgoon, Jr., <\/strong>CEO, Aeolus Pharmaceuticals, Inc., on catalytic antioxidants and Aeolus’ corporate strategy.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 155: November 3, 2006<\/h4>\n

\"155\"<\/strong>Marc Fisher, MD<\/strong>, Professor of Neurology, University of Massachusetts Medical School, on new approaches for clinical development of stroke therapies.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 153: October 20, 2006<\/h4>\n

\"153\"<\/strong>Eric Button<\/strong>, President and Managing Director, The BioMarker Group, on integrating biomarkers into drug development programs.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 152: October 13, 2006<\/h4>\n

\"152\"<\/strong>Alan Goldhammer<\/strong>, Associate Vice President Regulatory Affairs, Pharmaceutical Research and Manufacturers of America, on PhRMA’s views of the Institute of Medicine’s recommendations to improve drug safety.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 151: October 6, 2006<\/h4>\n

\"151\"<\/strong>Arthur M. Krieg, <\/strong>M.D., Senior Vice President, Research and Development, and Chief Scientific Officer, Coley Pharmaceutical Group, on Coley’s development of CpG oligonucleotide immunotherapeutics.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 150: September 29, 2006<\/h4>\n

\"150\"<\/strong>Brian P. Murphy,<\/strong> Partner, Morgan, Lewis & Bockius LLP, on unresolved issues in Hatch-Waxman settlement agreements.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 149: September 22, 2006<\/h4>\n

\"149b\"<\/strong>Mihael H. Polymeropoulos,<\/strong> M.D., CEO, and Chip Clark<\/strong>, Chief Business Officer, Vanda Pharmaceuticals, on Vanda’s genomics-based approach to product differentiation in the market for CNS treatments.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 148: September 15, 2006<\/h4>\n

\"148\"<\/strong>Gokhan S. Hotamisligil, <\/strong>M.D., Ph.D., Chair, Department of Genetics and Complex Diseases, Harvard School of Public Health, on chemical chaperones that suppress ER stress as potential treatments for diabetes.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 147: September 8, 2006<\/h4>\n

\"147\"<\/strong>Fumihiko Urano, <\/strong>M.D., Assistant Professor, University of Massachusetts Medical School, on the role of IRE1 in insulin biosynthesis in response to ER stress.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 145: August 25, 2006<\/h4>\n

\"145\"<\/strong>Bruce E. Schneider,<\/strong> Executive Vice President and Chief of Operations, Wyeth Research, on Wyeth\u2019s adoption of a \u201clearn and confirm\u201d approach to clinical development.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 144: August 11, 2006<\/h4>\n

\"144\"<\/strong>Duane Thurman,<\/strong> Director, Prescription Drug Program, Washington State Health Care Authority, on the state\u2019s preferred drug list and efforts to promote evidence-based, cost-effective prescribing behavior.<\/p>\n

\n
\n
\n

Issue 143: August 4, 2006<\/h4>\n

\"143\"<\/strong>Craig Atwood,<\/strong> Assistant Professor, Department of Medicine, University of Wisconsin, on the Reproductive-Cell Cycle Theory of Aging.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 141: July 21, 2006<\/h4>\n

\"141\"<\/strong>Hiromi Yoshikawa,<\/strong> Chairman and CEO, Otsuka America Pharmaceutical, Inc., on the expansion of Otsuka’s pharmaceutical business in the US.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 140: July 14, 2006:<\/h4>\n

\"140\"<\/strong>Daniel L. Weiner,<\/strong> Senior Vice President, Software Products, Pharsight Corporation, on Pharsight’s CRADA with the FDA and the infrastructure required for modeling and simulation in clinical development.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 139: July 7, 2006<\/h4>\n

\"139\"<\/strong>Garo H. Armen,<\/strong> Chairman and CEO, Antigenics Inc., on Oncophage, an experimental cancer vaccine using heat shock proteins.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 138: June 30, 2006<\/h4>\n

\"138\"<\/strong>Donald A. Berry<\/strong>, Chairman, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, on the use of Bayesian statistical methods in clinical development.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 136: June 16, 2006<\/h4>\n

\"136\"<\/strong>John E. McDonough,<\/strong> Executive Director, Health Care For All, on new legislation designed to reduce the number of people without health insurance in Massachusetts.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 135: June 9, 2006<\/h4>\n

\"135\"<\/strong>Robert J. Feeney, Jr.,<\/strong> President & CEO, MedVantx, on his company’s Sample Centers that dispense free generic drug samples.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 134: June 2, 2006<\/h4>\n

\"134\"<\/strong>Dr. Anthony Hayward,<\/strong> Director, Division of Clinical Research Resources, National Center for Research Resources, NIH, on a new Roadmap initiative to promote clinical research.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 133: May 26, 2006<\/h4>\n

\"133\"<\/strong>Dr. Steve E. Phurrough,<\/strong> Director, Coverage & Analysis Group, CMS, on National Coverage Determinations for Part B Drugs in Medicare.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 132: May 19 , 2006<\/h4>\n

\"132\"<\/strong>Dr. Randall S. Stafford, <\/strong>Assistant Professor of Medicine, Stanford Prevention Research Center, on new research in off-label prescribing patterns.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 131: May 12, 2006<\/h4>\n

\"131\"<\/strong>Dr. Bruce Silver,<\/strong> VP of Global Product Development Services in Oncology, PRA International, on issues in cancer drug development.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 129: April 21, 2006<\/h4>\n

\"129\"<\/strong>Dr. John T. Santini, Jr.<\/strong>, President, MicroCHIPS, Inc., on implantable devices for drug delivery.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 128: April 13, 2006<\/h4>\n

\"128\"<\/strong>Diana Conmy, <\/strong>Corporate Director of Market Insights at IMS Health, on key developments for the pharmaceutical industry in 2005.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 127: April 7, 2006<\/h4>\n

\"127\"<\/strong>Paul J. Hastings,<\/strong> President and Chief Executive Officer of Oncomed, Inc., on drugs to target cancer stem cells.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 126: March 31, 2006<\/h4>\n

\"126\"<\/strong>Dr. David Sinclair,<\/strong> Associate Professor of Pathology at Harvard Medical School, on the effects of SIR2 on the aging process.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 125: March 24, 2006<\/h4>\n

\"125\"<\/strong>Dr. Abner L. Notkins, <\/strong>Chief of Experimental Medicine for the National Institute of Dental and Craniofacial Research at the NIH, on the use of autoantibodies in predictive medicine.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 124: March 17, 2006<\/h4>\n

\"124\"<\/strong>Michael Valentino,<\/strong> Chief Consultant, PBM Strategic Healthcare Group, VA, on the VA\ufffdfs national formulary.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 123: March 10, 2006<\/h4>\n

\"123\"<\/strong>J.D. Kleinke,<\/strong> Chairman & Executive Director, Omnimedix Institute, on obstacles to the development of a viable HIT system.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 121:February 24, 2006<\/h4>\n

\"121\"<\/strong>Dr. Barry Davis<\/strong>, Principal Investigator & Director, ALLHAT Clinical Trials Center, on using the landmark ALLHAT results to change prescribing behavior.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 120: February 17, 2006<\/h4>\n

\"120\"<\/strong>Dr. Gerald Reaven,<\/strong> Professor Emeritus (Active) of Medicine, Stanford University, on insulin resistance syndrome.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 117: January 27, 2006<\/h4>\n

\"117\"<\/strong>Dr. Stanley Ip,<\/strong> Project Leader, and Dr. Peter Bonis<\/strong>, Primary Technical Expert, Tufts-New England Medical Center Evidence-based Practice Center, on the comparative effectiveness of treatments for gastroesophageal reflux disease.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 116: January 20, 2006<\/h4>\n

\"116\"<\/strong>Dr. Timothy Anderson<\/strong>, Senior Pharmaceutical Analyst, Prudential Equity Group, LLC, on pharmaceutical patent expirations in 2006.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 115:January 13, 2006<\/h4>\n

\"115\"<\/strong>Dr. Kazuko Nishikura,<\/strong> Professor, Gene Expression and Regulation Program, The Wistar Institute, on her research into RNA editing and microRNA.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 113: December 22, 2005<\/h4>\n

\"113\"<\/strong>Dr. Alice M. Rivlin, <\/strong>Senior Fellow in Economic Studies, The Brookings Institution, on the fiscal sustainability of Medicare spending.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 112:December 16, 2005<\/h4>\n

\"112\"<\/strong>James M. Karis<\/strong>, President & CEO, Entelos, Inc., on the role of in silico modeling in drug development.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 110: December 2, 2005<\/h4>\n

\"110\"<\/strong>Jerry Avorn<\/strong>, Professor of Medicine, Harvard Medical School, on academic detailing and physician prescribing behavior.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 109: November 18, 2005<\/h4>\n

\"109\"<\/strong>Kenneth I. Kaitin<\/strong>, Director, Tufts Center for the Study of Drug Development, on recent drug output trends.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 108: November 11, 2005<\/h4>\n

\"108\"<\/strong>Joan Alker<\/strong>, Senior Researcher, Georgetown Health Policy Institute, on Florida\u2019s proposed changes to the state Medicaid program.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 107: November 4, 2005<\/h4>\n

\"107\"<\/strong>Joshua Shinoff<\/strong>, Licensing Officer, Office of Technology Licensing, on technology transfer at UC Berkeley.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 105: October 21, 2005<\/h4>\n

\"105\"<\/strong>John A. Scarlett<\/strong>, President and CEO, Tercica, on the company\u2019s newly approved treatment for short stature.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 103: October 7, 2005<\/h4>\n

\"103\"<\/strong>Jean R. Slutsky<\/strong>, Director, Center for Outcomes and Evidence, on MMA provisions affecting the Agency for Healthcare Research and Quality.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 102: September 30, 2005<\/h4>\n

\"102\"<\/strong>Dara A. Corrigan<\/strong>, Partner, Arnold & Porter, on new MMA priorities for the Inspector General\u2019s Office at HHS.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 101: September 23, 2005<\/h4>\n

\"101\"<\/strong>Larry Gold<\/strong>, CEO & Chairman of the Board, SomaLogic, Inc., on the uses of aptamer technology.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 100: September 16, 2005<\/h4>\n

\"100\"<\/strong>Larry D. Sasich<\/strong>, Staff Pharmacist, Public Citizen, on drug safety issues at the FDA.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 99: September 9, 2005<\/h4>\n

\"99\"<\/strong>Mark Heesen,<\/strong>President, National Venture Capital Association, on venture capital financing trends in the biotech industry.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 98: September 2, 2005<\/h4>\n

\"98\"<\/strong>Dr. John A. Gans<\/strong>, EVP and CEO, American Pharmacists Association, on the role of pharmacists in improving drug safety.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 97: August 26, 2005<\/h4>\n

\"97\"<\/strong>David Largaespada,<\/strong>Associate Professor, University of Minnesota Cancer Center, on a new method of cancer-gene identification using the Sleeping Beauty transposon.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 96: August 12, 2005<\/h4>\n

\"96\"<\/strong>Makoto Nishimura, <\/strong>President and CEO of Astellas Pharma US, Inc. on Astellas\u2019s strategy in U.S. market.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 93: July 22, 2005<\/h4>\n

\"93\"<\/strong>Sharon Anglin Treat,<\/strong> Executive Director, National Legislative Association on Prescription Drug Prices, on state-level initiatives to reduce prescription drug prices..<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 92: July 15, 2005<\/h4>\n

\"92\"<\/strong>Dr. Moriya Tsuji, <\/strong>Associate Professor, Aaron Diamond AIDS Research Center, Rockefeller University, on the discovery of new antigens that bind to the CD1d receptor and activate NKT cells.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 91: July 8, 2005<\/h4>\n

\"91\"<\/strong>Larry McComber,<\/strong> VP Contract and Program Services, Novation LLC, on GPO contracting for prescription drugs.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 90: July 1, 2005<\/h4>\n

\"90\"<\/strong>Robert K. Passikoff, <\/strong>Founder and President, Brand Keys, Inc., on DTC corporate and product brand promotion.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 89: June 24, 2005<\/h4>\n

\"89\"<\/strong>Jeffrey I.D. Lewis,<\/strong> Partner, Patterson Belknap Webb & Tyler LLP, on the impact of the Integra v. Merck decision on pharmaceutical research.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 88: June 17, 2005<\/h4>\n

\"88\"<\/strong>Shabbir Dahod, <\/strong>President and CEO, SupplyScape Corporation, on developing an electronic pedigree for the pharmaceutical supply chain.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 86: May 27, 2005<\/h4>\n

\"86\"<\/strong>Michael Rosen,<\/strong> Chairman and CEO, Immune Cell Therapy, Inc., on the life sciences hub in the Midwest.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 84: May 13, 2005<\/h4>\n

\"84\"<\/strong>Gary Zammit, <\/strong>President and CEO, Clinilabs, Inc., on progress in developing treatments for sleep disorders.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 80: April 15, 2005<\/h4>\n

\"80\"<\/strong>Frank M. Rapoport,<\/strong> Partner, McKenna Long & Aldridge LLP, on the BioShield legislation and the development of a biodefense industry.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 78: April 1, 2005<\/h4>\n

\"78\"<\/strong>Steve Powell, <\/strong>Vice President of Worldwide Sales, Phase Forward, Incorporated, on the use of electronic data capture in clinical trials<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 77: March 25, 2005<\/h4>\n

\"77\"<\/strong>Christopher Watts,<\/strong> Staff Fellow, Center for Drug Evaluation and Research, FDA, on moving to real time release with PAT.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 76: March 18, 2005<\/h4>\n

\"76\"<\/strong>Daniel Devine,<\/strong> President and CEO, Acceptys, Inc., on shifting from humanized to fully-human monoclonal antibodies.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 75: March 11, 2005<\/h4>\n

\"75\"Alton C. Morgan<\/strong>, Chairman and President, InNexus Biotechnology, Inc., on the development of SuperAntibodies.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 73: February 25, 2005<\/h4>\n

\"73\"Paul Cusenza<\/strong>, Vice President, Alliance Management, Perlegen Sciences, Inc., on Perlegen\u2019s approach to high-density, whole genome SNP genotyping.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 72: February 18, 2005<\/h4>\n

\"72\"Derek Guyton<\/strong>, Principal, Mercer Human Resources Consulting, on how employer-sponsored retiree drug benefits are being affected by the MMA.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 69: January 28, 2005<\/h4>\n

\"69\"Steven H. Sklar<\/strong>, Partner, Leydig, Voit & Mayer, Ltd., on the Teva v. Pfizer decision on declaratory judgment actions.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 68: January 21, 2005<\/h4>\n

\"68\"Vera Hassner Sharav<\/strong>, President, Alliance for Human Research Protection, on how industry practices in clinical trials have led to an erosion of public trust.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 65: December 24, 2004<\/h4>\n

\"65\"Maxine Gowen<\/strong>, Managing Partner, SR One, on the investment approach of a venture capital subsidiary of a major pharmaceutical company.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 64: December 17, 2004<\/h4>\n

\"64\"Jennifer Covich Bordenick, MA,<\/strong> Director of Strategic Programs, eHealth Initiative, on the adoption of e-prescribing.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 63: December 10, 2004<\/h4>\n

\"63\"John Santa<\/strong>, Medical Director of the Center for Evidence-based Policy at Oregon Health and Science University, on state initiatives to create a transparent drug evaluation system for more cost-effective drug spending.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 61: November 19, 2004<\/h4>\n

\"61\"J. David Haddox<\/strong>, Vice President, Risk Management & Health Policy, Purdue Pharma, on a government-aided, multifaceted approach to reduce the potential for abuse of prescription pain treatments.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 59: November 5, 2004<\/h4>\n

\"59\"<\/strong>Mark Merritt<\/strong>, President and CEO, Pharmaceutical Care Management Association, on the role of pharmacy benefit managers in the Medicare prescription drug benefit.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 57: October 22, 2004<\/h4>\n

\"57\"<\/strong>Joseph S. McCracken<\/strong>, Vice President, Business Development, Genentech, Inc., on Genentech’s approach to R&D and commercialization partnerships.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 56: October 15, 2004<\/h4>\n

\"56\"Kathleen Jaeger, <\/strong>President and CEO, Generic Pharmaceutical Association, on the scientific advancements facilitating regulatory evaluations of biogenerics.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 55: October 8, 2004<\/h4>\n

\"55\"<\/strong>Richard C. Aulatta<\/strong>, President, R.C. Auletta and Co., on Merck’s handling of the Vioxx recall.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 52: September 17, 2004<\/h4>\n

\"52\"Michael Krensavage<\/strong>, Senior Vice President, Equity Research, Raymond James & Associates, on Schering-Plough’s turnaround strategy.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 51: September 10, 2004<\/h4>\n

\"51\"<\/strong>Richard D. Kelly<\/strong>, Senior Partner, Oblon, Spivak, McClelland, Maier & Neustadt, P.C., on issues relating to authorized generics.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 49: August 20, 2004<\/h4>\n

\"49\"Jeffrey Aronin<\/strong>, Founder, President and COO, Ovation Pharmaceuticals, on Ovation’s niche market business strategy.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 48: August 13, 2004<\/h4>\n

\"48\"Nobuya Oka<\/strong>, Executive Vice President, Takeda Pharmaceuticals North America, on Takeda’s strategy in the U.S. market.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 47: August 6, 2004<\/h4>\n

\"47\"Reeta Roy<\/strong>, Vice President, Global Citizenship and Policy, Abbott Laboratories, on Abbott’s AIDS initiatives in developing countries.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 45: July 23, 2004<\/h4>\n

\"45\"Kevin Outterson<\/strong>, Associate Professor of Law, West Virginia University, on the impact of the Australia-U.S. Free Trade Agreement on the market for pharmaceuticals.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 44: July 16, 2004<\/h4>\n

\"44\"Vamsi K. Mootha<\/strong>, M.D., Assistant Professor, Harvard Medical School, on the team-science approach to biomedical research.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 43: July 9, 2004<\/h4>\n

\"43\"Michael M. Gottesman<\/strong>, M.D., Deputy Director for Intramural Research, NIH, on intramural research at the NIH.<\/em><\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 42: July 2, 2004<\/h4>\n

\"42\"<\/strong>Barry Greene<\/strong>, Chief Operating Officer, Alnylam Pharmaceuticals, on RNAi therapeutics.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 41: June 25, 2004<\/h4>\n

\"41\"<\/strong>Carl B. Feldbaum<\/strong>, President, Biotechnology Industry Organization (BIO), on the development of BIO and the biotech industry during his tenure.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 40: June 18, 2004<\/h4>\n

\"40\"<\/strong>Donald W. Moran<\/strong>, President, The Moran Company, on New York Attorney General Eliot Spitzer’s fraud suit against GlaxoSmithKline.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 37: May 28, 2004<\/h4>\n

\"37\"<\/strong>Frank F. Bilstein <\/strong>(Left), Partner, and Razmic S. Gregorian, Jr. <\/strong>(Right), Director, Simon-Kucher & Partners, on the impact of the Medicare legislation on the environment for drug pricing in the U.S.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 36: May 21, 2004<\/h4>\n

\"36\"Robert Monaghan <\/strong>(Left), CEO, and Lawrence K. Cohen <\/strong>(Right), Vice Chairman, Zyomyx Inc., on the use of protein chips in drug development.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 35: May 14, 2004<\/h4>\n

\"35\"Viren Mehta<\/strong>, Managing Member, Mehta Partners LLC, on the merits of the Sanofi-Aventis merger .<\/em><\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 34: May 7, 2004<\/h4>\n

\"34\"John Rother<\/strong>, Director of Policy and Strategy, AARP, on the new Medicare drug discount cards and legislative reform priorities for Medicare.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 32: April 23, 2004<\/h4>\n

\"32\"Merrill Goozner<\/strong>, Journalist and Project Director, Center for Science in the Public Interest, on his new book, The $800 Million Pill.<\/em><\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 31: April 16, 2004<\/h4>\n

\"31\"Josef H. von Rickenbach<\/strong>, Chairman and CEO, PAREXEL International, on current trends in clinical development.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 30: April 9, 2004<\/h4>\n

\"30\"Scott Gottlieb<\/strong>, M.D.,Director of Medical Policy Development, FDA, on Mark McClellan’s tenure at the FDA. .<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

ssue 29: April 2, 2004<\/h4>\n

\"29\"Wayne Koberstein<\/strong>, Contributing Editor, Contract Pharma, on globalization, consolidation, and pharmaceutical market strategies.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 28: March 26, 2004<\/h4>\n

\"28\"Barbara Yanni<\/strong>, Chief Licensing Officer and Vice President, Merck & Co., Inc., on Merck\u2019s in-licensing activities.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 27: March 19, 2004<\/h4>\n

\"27\"Steven Rauscher<\/strong>, President and CEO, Genome Therapeutics, on the market launch of Factive.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 26: March 12, 2004<\/h4>\n

\"26\"Richard Trabert<\/strong>, Public affairs consultant and faculty member at Boston College\u2019s Center for Corporate Citizenship, on social initiatives in the pharmaceutical industry.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 25: March 5, 2004<\/h4>\n

\"25\"<\/strong>Lowell E. Schnipper<\/strong>, M.D., Harvard Medical School Professor and Chief of Hematology and Oncology at Beth Israel Deaconess Medical Center, on synergies between new and existing treatments in oncology.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 24: February 27, 2004<\/h4>\n

\"24\"Soichi Matsuno<\/strong>, Chairman, Eisai Inc., on Eisai\u2019s strategy in the U.S. market.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 23: February 20, 2004<\/h4>\n

\"23\"<\/strong>Donald O. Beers<\/strong>, Partner, Arnold & Porter, on polymorph patents.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 22: February 13, 2004<\/h4>\n

\"22\"Ken Araki<\/strong>, Pharmaceutical Industry Global Research Director, Nomura Securities International, on the forces shaping change in the pharmaceutical industry.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 21: February 6, 2004<\/h4>\n

\"21\"Jean-Paul Modde<\/strong>, Group President, Dendrite International, Inc., on new trends in CRM in the pharmaceutical industry.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 19: January 23, 2004<\/h4>\n

\"19\"Kevin Goodno<\/strong>, Commissioner, Minnesota Department of Human Services, on Minnesota\u2019s initiatives toward prescription drug importation.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 18: January 16,2004<\/h4>\n

\"18\"Preston Henske<\/strong>, Vice President, Bain & Company, on building a new business model in the pharmaceutical industry.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 15: December 12, 2003<\/h4>\n

\"15\"Kenneth S. Abramowitz<\/strong>, Senior Advisor, The Carlyle Group, on the impact of Medicare reforms on the HMO industry.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 14: December 5, 2003<\/h4>\n

\"14\"Anthony Robbins, M.D.<\/strong>, Professor of Public Health, Tufts University School of Medicine, on Medicare reform in historical perspective.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 12: November 21, 2003<\/h4>\n

\"12\"Louis M. Solomon<\/strong>, Partner, Proskauer Rose LLP, on Hatch-Waxman reforms.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 11: November 14, 2003<\/h4>\n

\"11\"Sharon Treat<\/strong>, Senate Majority Leader, State of Maine, on Maine\u2019s initiatives to lower the cost of prescription drugs.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 10: November 7, 2003<\/h4>\n

\"10\"Nick Naclerio<\/strong>, President, ParAllele BioSciences, on pushing the boundaries of high-throughput SNP genotyping.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 9: October 31, 2003<\/h4>\n

\"9\"Vibeke Strand, M.D.<\/strong>, Adjunct Clinical Professor, Division of Immunology, Stanford University, on new treatment therapies for rheumatiod arthritis.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 7: October 17, 2003<\/h4>\n

\"\"<\/strong>Christopher D.<\/strong> Hook<\/strong>, Director for RFID Market Development & Deborah H. Murphy, Life Sciences Market Development Manager, Zebra Technologies, on technologies for pharmaceutical supply chains.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 6: October 10, 2003<\/h4>\n

\"6\"Brian G. Atwood,<\/strong> Managing Director, Versant Ventures, on biotech venture capital investing and market cycles.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 5: October 3, 2003<\/h4>\n

\"5\"Glenn Rice<\/strong>, Vice President for Biopharmaceutical Sciences, SRI International, on bridging the gap from university research labs to clinical trials.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 4: September 26, 2003<\/h4>\n

\"\"Eric Lindsey<\/strong>, Vice President for Business Development, PDI Inc., on salesforce outsourcing.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 3: September 19, 2003<\/h4>\n

\"\"Jack Trout<\/strong>, President, Trout & Partners, Ltd., on product positioning through DTC advertising.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n

\n
\n
\n

Issue 2: September 12, 2003<\/h4>\n

\"\"Tom Heyman<\/strong>, Executive Vice President for Business Development, Johnson & Johnson, on J&J\u2019s in-licensing activities.<\/p>\n<\/div>\n<\/div>\n<\/td>\n

\n
\n
\n

Issue 1: September 5, 2003<\/h4>\n

\"\"Paula Campbell Evans<\/strong>, Partner, Palmer & Dodge LLP, on the regulatory prospects for generic biologics.<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Recent interviews Archive Interviews through 2022 Issue 367: April 1, 2011 Scott Minick, President and CEO, BIND Biosciences, on the company’s therapeutic targeted nanoparticle technology. Issue 366: March 25, 2011 Robert Shore, M.D., CEO, and Timothy Sullivan, Executive Vice President, Cornerstone Pharmaceuticals, on the company\u2019s drug delivery technology targeting cancer cell metabolism. Issue 364: March […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-100","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/www.msapr.com\/main\/wp-json\/wp\/v2\/pages\/100","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.msapr.com\/main\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.msapr.com\/main\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.msapr.com\/main\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.msapr.com\/main\/wp-json\/wp\/v2\/comments?post=100"}],"version-history":[{"count":28,"href":"https:\/\/www.msapr.com\/main\/wp-json\/wp\/v2\/pages\/100\/revisions"}],"predecessor-version":[{"id":686,"href":"https:\/\/www.msapr.com\/main\/wp-json\/wp\/v2\/pages\/100\/revisions\/686"}],"wp:attachment":[{"href":"https:\/\/www.msapr.com\/main\/wp-json\/wp\/v2\/media?parent=100"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}